Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Significance of Polar Charged Amino Acids in Compound Mutations in EGFR-mutated Patients Treated With First-line Afatinib.

In vivo (Athens, Greece) - 1 Jan 2000

Satoh Hiroaki, Sasatani Yuika, Miyazaki Kunihiko, Sato Yoshiharu, Hizawa Nobuyuki

Abstract excerpt

BACKGROUND/AIM: Next-generation sequencing (NGS) has recently made it possible to investigate polar charged amino acids in compound mutations in the epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Several preclinical studies have suggested the involvement of polar charged amino acids in the treatment of EGFR mutations and EGFR-tyrosine kinase inhibitors (TKIs). With this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Amino Acids
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Genes, erbB-1

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 35738583
DOI: 10.21873/invivo.12899
PMCID: PMC9301438

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Significance of Polar Charged Amino Acids in Compound Mutations in EGFR-mutated Patients Treated With First-line Afatinib.PMID 35738583Read ↗

Impact of compound mutations I1171N + F1174I and I1171N + L1198H on the structure of ALK in NSCLC pathogenesis: atomistic insights.Semantic proximity Read ↗

Compound<i>EGFR</i>mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinomaSemantic proximity Read ↗

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence.Semantic proximity Read ↗

Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations.Semantic proximity Read ↗

EGFR G719X + S768I co-mutations in NSCLC: genomic landscape and differential responses to EGFR-TKIs in a large real-world cohort.Semantic proximity Read ↗

The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): 'Where the streets have no name'.Semantic proximity Read ↗

Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.